What is Quick Biology?
Quick Biology operates as a specialized CLIA- and CAP-certified genomic center, providing critical infrastructure for next-generation sequencing (NGS) and advanced bioinformatics. The firm serves a diverse clientele, ranging from academic research institutions to large-scale biopharma enterprises, by delivering precise whole exome and RNA sequencing services. Their market position is defined by a commitment to client-oriented customization, ensuring that researchers receive high-fidelity genomic data that is both cost-effective and delivered within rigorous timelines. By bridging the gap between complex laboratory workflows and actionable clinical insights, Quick Biology remains a pivotal partner in the global life sciences ecosystem.
How much funding has Quick Biology raised?
Quick Biology has raised a total of $58K across 1 funding round:
Debt
$58K
Debt (2021): $58K with participation from PPP
Key Investors in Quick Biology
PPP
Public-Private Partnership
What's next for Quick Biology?
With the infusion of this recent capital, Quick Biology is expected to accelerate its strategic roadmap, focusing on the expansion of its NGS throughput and the refinement of its proprietary bioinformatics pipelines. As the demand for high-quality genomic data continues to surge within the biopharma sector, the company is likely to prioritize investments in automated laboratory technologies and talent acquisition to maintain its competitive edge. This phase of development will likely involve deepening its integration into clinical diagnostic workflows, thereby solidifying its reputation as a premier provider of scalable genomic solutions for both research and therapeutic development applications.
See full Quick Biology company page
